GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » Gross Profit

Talaris Therapeutics (Talaris Therapeutics) Gross Profit : $0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics Gross Profit?

Talaris Therapeutics's gross profit for the three months ended in Jun. 2023 was $0.00 Mil. Talaris Therapeutics's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Talaris Therapeutics's gross profit for the three months ended in Jun. 2023 was $0.00 Mil. Talaris Therapeutics's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Talaris Therapeutics's Gross Margin % for the quarter that ended in Jun. 2023 was N/A%.

Talaris Therapeutics had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Talaris Therapeutics Gross Profit Historical Data

The historical data trend for Talaris Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talaris Therapeutics Gross Profit Chart

Talaris Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross Profit
- - - -

Talaris Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Talaris Therapeutics's Gross Profit

For the Biotechnology subindustry, Talaris Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talaris Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Talaris Therapeutics's Gross Profit falls into.



Talaris Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Talaris Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Talaris Therapeutics's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Talaris Therapeutics's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Talaris Therapeutics  (NAS:TALS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Talaris Therapeutics had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Talaris Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Talaris Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Talaris Therapeutics (Talaris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
93 Worcester Street, Wellesley, MA, USA, 02481
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
Executives
Cariad Chester director C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung officer: Chief Medical Officer C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff officer: CBO, GC and Secretary 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff director C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni director, officer: CEO 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson officer: Chief Regulatory Officer C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson officer: Interim CFO C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara director C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones officer: Chief Technology Officer C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad director, 10 percent owner, officer: Chief Scientific Officer C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt director, officer: See Remarks 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025